Skip to main content

Cell Genesis Announces CEXCI Cord Protein Banking, Which Will Revolutionize Medical Therapies As Much As Umbilical Cord Blood Banking Does

Petaling Jaya, Selangor, Malaysia, 23rd Aug 2023 – In a monumental stride towards transformative medical treatments, CEXCI Cord Protein Banking by Cell Genesis and Umbilical Cord Blood Banking have emerged as pioneering methodologies for preserving valuable biological resources sourced from the umbilical cord. These cutting-edge techniques have garnered widespread attention for their potential applications in regenerative medicine and blood-related disorder treatments.

CEXCI Cord Protein Banking: A Paradigm Shift in Regenerative Medicine

At the forefront of medical breakthroughs, CEXCI Cord Protein Banking by Cell Genesis, a biotechnology company founded by Dr. Michael Lim, entails the extraction and preservation of the remarkable CEXCI proteins, derived from the umbilical cord tissues. Revered for its unrivaled regenerative properties, the CEXCI proteins hold significant potential for diverse medical applications. The primary focus of CEXCI Cord Protein Banking is to preserve these invaluable proteins for future therapeutic uses, harnessing their capacity to stimulate the regenerative potential inherent in the recipient’s own stem cells.

A distinguishing feature of CEXCI Cord Protein therapy lies in its liberating departure from the stringent Human Leukocyte Antigen (HLA) matching process inherent in traditional hematopoietic stem cell transplantation. Successful engraftment in conventional transplantation heavily relies on finding the closest HLA match to minimize the risks of graft rejection and Graft-versus-host disease (GVHD). However, CEXCI Cord Protein therapy eliminates the need for HLA matching, as the protein functions as a signaling molecule, prompting the recipient’s stem cells to initiate regenerative processes independently.

This revolutionary attribute significantly broadens the pool of eligible recipients for CEXCI Cord Protein therapy, presenting an optimistic alternative for patients without needing a closely matched sibling or parental donors. This advancement holds the potential to revolutionize regenerative medicine, promising widespread adoption in the quest for transformative therapies.

Umbilical Cord Blood Banking: Unleashing the Power of Hematopoietic Stem Cells

In striking contrast to CEXCI Cord Protein Banking, Umbilical Cord Blood Banking revolves around the collection and preservation of blood sourced from the umbilical cord immediately after childbirth. This umbilical cord blood harbors a wealth of hematopoietic stem cells, renowned for their remarkable ability to differentiate into various blood cell types. These stem cells offer a promising treatment avenue for an array of blood-related disorders, especially hematological malignancies.

Hematopoietic stem cell transplantation facilitated by umbilical cord blood hinges on identifying the closest HLA match between the donor and recipient. This meticulous matching process, often fulfilled by siblings or parents, ensures the transplant’s success and minimizes potential complications. Medical professionals specializing in blood stem cell transplantation make individualized decisions regarding the ideal donor and transplant approach on a case-by-case basis, prioritizing the best possible outcome for the recipient.

Conclusion: Shaping the Future of Medical Therapies

In summary, CEXCI Cord Protein Banking and Umbilical Cord Blood Banking epitomize distinct methodologies for preserving biological resources from the umbilical cord, each offering diverse applications in regenerative medicine and blood-related disorder treatments, respectively. While CEXCI Cord Protein Banking capitalizes on the CEXCI proteins’ regenerative ability to empower the body’s regenerative processes, whereas Umbilical Cord Blood Banking harnesses the potential of hematopoietic stem cells for transformative blood stem cell transplantation.

The fundamental difference between these approaches lies in their utilization and HLA matching requirements. CEXCI Cord Protein Therapy’s capacity to bypass HLA matching offers an exciting avenue for regenerative medicine research and presents a promising option for patients seeking alternatives to conventional transplantation. On the other hand, Umbilical Cord Blood Banking continues to be an invaluable resource for treating blood-related disorders, where HLA matching remains pivotal for ensuring successful transplantations.

Both CEXCI Cord Protein Banking and Umbilical Cord Blood Banking stand as a testament to the remarkable advancements in medical science, offering a ray of hope and life-changing treatments to patients worldwide.

About Cell Genesis:

Cell Genesis, founded by Dr Michael Lim, is a leading biotechnology company dedicated to advancing the frontiers of science and medicine. They specialize in innovative research, development, and commercialization of cutting-edge technologies aimed at transforming healthcare and improving patient outcomes. With a strong focus on stem cell technology, they are committed to pushing boundaries, driving discoveries, and bringing revolutionary therapies to the forefront of modern medicine.

For more information, please visit the official website:

Media Contact

Organization: Cell Genesis

Contact Person: Dr. Michael Lim Ming Soon



Contact Number: ‎+60 3-7622 2991

City: Petaling Jaya

State: Selangor

Country: Malaysia

Release Id: 2308235622

The post Cell Genesis Announces CEXCI Cord Protein Banking, Which Will Revolutionize Medical Therapies As Much As Umbilical Cord Blood Banking Does appeared first on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

Information contained on this page is provided by an independent third-party content provider. eTrendystock make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.